Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationTop up the gaps, then interpret
Decipher Plus
For when your existing report is almost enough. We test only the missing pieces, so you pay for the gap and not the whole test again.
When your report is almost enough
Rather than re-run everything, we test only the missing pieces, then combine the top-up with your existing data to produce a complete decision. You pay for the gap, not the whole test again.
Missing immune markers
Your report has drivers but no TMB or MSI.
Missing drug safety
Pharmacogenomics or other markers needed for a safe plan are absent.
How it works
- Step 1Gap analysis
We identify exactly what is missing for a complete plan.
- Step 2Targeted top-up
Only the missing markers are tested. Nothing redundant.
- Step 3Merge and interpret
Top-up and existing data run through the engine together.
- Step 4KPCIRC sign-out
A full, signed Blueprint Care decision.
Why it saves money
Re-testing what you already have is waste.
Decipher Plus respects the investment you have already made and adds only what is genuinely needed, which is both cheaper and faster.
Being clear about our limits
What we do and do not do
What we DO
- Re-annotate every alteration against current knowledge
- Apply all six intelligence layers and match trials, biosimilars and access
- Return a complete, tumour-board-signed decision
- Tell you honestly when your data is not complete enough
What we DON’T do
- Diagnose or decide treatment on its own
- Interpret markers your original report never measured
- Present an incomplete picture as complete
- Guarantee drug availability, approval, cover or benefit
Plain-language glossary (4 terms)
| Term | What it means |
|---|---|
| Interpretation | Turning an existing variant list into a ranked, evidenced decision. |
| Top-up | A small, targeted test to fill one missing marker such as TMB, MSI or PGx. |
| MTB | Molecular tumour board, the licensed panel that signs the final decision. |
| VUS | Variant of uncertain significance, a change whose meaning is not yet clear. |
Important information and regulatory status
Decipher and Decipher Plus is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.
- A result is not a diagnosis and does not by itself decide treatment.
- A “not detected” result does not rule out cancer or a genetic change.
- Not all cancers release enough DNA into blood to be detected.
- We cannot guarantee that a medicine will be available, approved, covered or effective.
- Collection kits are for qualified phlebotomists. They are not for self-testing.
- Confirmatory testing may be required.
Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner holding NABL (ISO 15189), CAP and CLIA accreditation, following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal